Drug repositioning: Difference between revisions
Content deleted Content added
Corrected the repurposing definition. Removed ads by companies. Tags: references removed Visual edit |
m Added article for further reading |
||
| Line 12: | Line 12: | ||
== Further reading == |
== Further reading == |
||
{{refbegin}} |
{{refbegin|}} |
||
* {{cite journal |
* {{cite journal|last=|first=|vauthors=Chong CR, Sullivan DJ|title=New uses for old drugs|url=|journal=Nature|volume=448|issue=7154|pages=645–6|date=August 2007|pmid=17687303|via=|doi=10.1038/448645a}} |
||
* {{cite journal |
* {{cite journal|last=|first=|vauthors=Tartaglia LA|title=Complementary new approaches enable repositioning of failed drug candidates|url=|journal=Expert Opinion on Investigational Drugs|volume=15|issue=11|pages=1295–8|date=November 2006|pmid=17040191|via=|doi=10.1517/13543784.15.11.1295}} |
||
* {{cite journal |
* {{cite journal|last=|first=|vauthors=Aronson JK|title=Old drugs--new uses|url=|journal=British Journal of Clinical Pharmacology|volume=64|issue=5|pages=563–5|date=November 2007|pmid=17935601|via=|pmc=2203255|doi=10.1111/j.1365-2125.2007.03058.x}} |
||
*{{Cite journal|last=|first=|vauthors=Pritchard JL, O'Mara TA, Glubb DM|date=December 2017|title=Enhancing the promise of drug repositioning through genetics|url=https://www.frontiersin.org/articles/10.3389/fphar.2017.00896/full|journal=Frontiers in Pharmacology|volume=8|pages=896|pmid=29270124|via=}}{{refend}} |
|||
{{refend}} |
|||
[[Category:Pharmaceutical industry]] |
[[Category:Pharmaceutical industry]] |
||
[[Category:Drug discovery]] |
[[Category:Drug discovery]] |
||
Revision as of 07:52, 14 November 2018
Drug repositioning (most times confused with drug repurposing) is the application of already approved drugs and compounds to treat a different disease.[1]
Drug repurposing on the other hand is re-investigating existing drugs that failed approval for new therapeutic indications.
Using drug repositioning, pharmaceutical companies have achieved a number of successes; for example, Pfizer's Viagra for erectile dysfunction and Celgene's thalidomide for cancer.[2][3]
See also
References
- ^ Sleigh, Sara H.; Barton, Cheryl L. (23 August 2012). "Repurposing Strategies for Therapeutics". Pharmaceutical Medicine. 24 (3): 151–159. doi:10.1007/BF03256811.
{{cite journal}}: Unknown parameter|name-list-format=ignored (|name-list-style=suggested) (help) - ^ Ashburn TT, Thor KB (August 2004). "Drug repositioning: identifying and developing new uses for existing drugs". Nature Reviews. Drug Discovery. 3 (8): 673–83. doi:10.1038/nrd1468. PMID 15286734.
- ^ Institute of Medicine (2014). Drug Repurposing and Repositioning: Workshop Summary. National Academies Press. ISBN 978-0-309-30204-3.
Further reading
- Chong CR, Sullivan DJ (August 2007). "New uses for old drugs". Nature. 448 (7154): 645–6. doi:10.1038/448645a. PMID 17687303.
- Tartaglia LA (November 2006). "Complementary new approaches enable repositioning of failed drug candidates". Expert Opinion on Investigational Drugs. 15 (11): 1295–8. doi:10.1517/13543784.15.11.1295. PMID 17040191.
- Aronson JK (November 2007). "Old drugs--new uses". British Journal of Clinical Pharmacology. 64 (5): 563–5. doi:10.1111/j.1365-2125.2007.03058.x. PMC 2203255. PMID 17935601.
- Pritchard JL, O'Mara TA, Glubb DM (December 2017). "Enhancing the promise of drug repositioning through genetics". Frontiers in Pharmacology. 8: 896. PMID 29270124.